365 related articles for article (PubMed ID: 28061982)
21. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA.
Bogeljić Patekar M; Milunović V; Mišura Jakobac K; Perica D; Mandac Rogulj I; Kursar M; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2018 Sep; 57(3):542-553. PubMed ID: 31168188
[TBL] [Abstract][Full Text] [Related]
22. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.
Shouse G; Danilova OV; Danilov AV
Curr Opin Oncol; 2022 Sep; 34(5):540-545. PubMed ID: 35855508
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
24. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
25. Idelalisib: targeting PI3Kδ in B-cell malignancies.
Gilbert JA
Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
[No Abstract] [Full Text] [Related]
26. Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas.
Madanat YF; Smith MR; Almasan A; Hill BT
Blood Lymphat Cancer; 2016; 6():1-6. PubMed ID: 27375364
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
28. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
29. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
30. Idelalisib: first global approval.
Markham A
Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
[TBL] [Abstract][Full Text] [Related]
31. Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis.
Banerjee T; Kim MS; Haslam A; Prasad V
JAMA Intern Med; 2023 May; 183(5):435-441. PubMed ID: 36939665
[TBL] [Abstract][Full Text] [Related]
32. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
Rosenthal A
Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
[TBL] [Abstract][Full Text] [Related]
33. Copanlisib in the treatment of non-Hodgkin lymphoma.
Narkhede M; Cheson BD
Future Oncol; 2020 Sep; 16(26):1947-1955. PubMed ID: 32658557
[TBL] [Abstract][Full Text] [Related]
34. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.
Siddiqi T; Rosen ST
Oncology (Williston Park); 2015 Mar; 29(3):198-203. PubMed ID: 25772456
[TBL] [Abstract][Full Text] [Related]
35. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
Mato A; Jauhari S; Schuster SJ
Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
[TBL] [Abstract][Full Text] [Related]
36. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
Patel K; Danilov AV; Pagel JM
Blood; 2019 Nov; 134(19):1573-1577. PubMed ID: 31554637
[TBL] [Abstract][Full Text] [Related]
37. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
38. Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A; Colbert A; Lechowicz MJ; Flowers CR
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):514-8. PubMed ID: 26297176
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.
Ujjani C; Cheson B
Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533
[TBL] [Abstract][Full Text] [Related]
40. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]